News Snapshot:
On August 4, Galixir, which uses artificial intelligence technology to empower drug research and development, announced the completion of a new round of financing. This round of financing was led by the Shanghai Artificial Intelligence Industry Investment Fund, and received continued investment from all old shareholders including Gaorong Capital, Source Code Capital, Red Dot China, DCM, Wuyuan Capital, and BAI Capital. Star Pharmaceutical Technology stated that this round of financing has played an important role in further consolidating the company’s platform functions. Talent team and deepen the advantages of scientific research and technology. The company will work with investors to...
